Literature DB >> 34800285

Cannabis-Based Medicines and Medical Cannabis in the Treatment of Nociplastic Pain.

Mary-Ann Fitzcharles1,2, Frank Petzke3, Thomas R Tölle4, Winfried Häuser5,6.   

Abstract

Nociplastic pain is defined as pain due to sensitization of the nervous system, without a sufficient underlying anatomical abnormality to explain the severity of pain. Nociplastic pain may be manifest in various organ systems, is often perceived as being more widespread rather than localized and is commonly associated with central nervous system symptoms of fatigue, difficulties with cognition and sleep, and other somatic symptoms; all features that contribute to considerable suffering. Exemplified by fibromyalgia, nociplastic conditions also include chronic visceral pain, chronic headaches and facial pain, and chronic musculoskeletal pain. It has been theorized that dysfunction of the endocannabinoid system may contribute to persistent pain in these conditions. As traditional treatments for chronic pain in general and nociplastic pain in particular are imperfect, there is a need to identify other treatment options. Cannabis-based medicines and medical cannabis (MC) may hold promise and have been actively promoted by the media and advocacy. The medical community must be knowledgeable of the current evidence in this regard to be able to competently advise patients. This review will briefly explain the understanding of nociplastic pain, examine the evidence for the effect of cannabinoids in these conditions, and provide simplified guidance for healthcare providers who may consider prescribing cannabinoids for these conditions.
© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34800285     DOI: 10.1007/s40265-021-01602-1

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  71 in total

Review 1.  Do we need a third mechanistic descriptor for chronic pain states?

Authors:  Eva Kosek; Milton Cohen; Ralf Baron; Gerald F Gebhart; Juan-Antonio Mico; Andrew S C Rice; Winfried Rief; A Kathleen Sluka
Journal:  Pain       Date:  2016-07       Impact factor: 6.961

Review 2.  Pathophysiology of irritable bowel syndrome.

Authors:  Gerald J Holtmann; Alexander C Ford; Nicholas J Talley
Journal:  Lancet Gastroenterol Hepatol       Date:  2016-09-08

Review 3.  The "Biology-First" Hypothesis: Functional disorders may begin and end with biology-A scoping review.

Authors:  P Enck; N Mazurak
Journal:  Neurogastroenterol Motil       Date:  2018-06-28       Impact factor: 3.598

Review 4.  Overlapping Chronic Pain Conditions: Implications for Diagnosis and Classification.

Authors:  William Maixner; Roger B Fillingim; David A Williams; Shad B Smith; Gary D Slade
Journal:  J Pain       Date:  2016-09       Impact factor: 5.820

Review 5.  Comorbid fibromyalgia: A qualitative review of prevalence and importance.

Authors:  M-A Fitzcharles; S Perrot; W Häuser
Journal:  Eur J Pain       Date:  2018-06-22       Impact factor: 3.931

Review 6.  Central sensitization: implications for the diagnosis and treatment of pain.

Authors:  Clifford J Woolf
Journal:  Pain       Date:  2010-10-18       Impact factor: 6.961

Review 7.  Neurotrophins, endocannabinoids and thermo-transient receptor potential: a threesome in pain signalling.

Authors:  Isabel Devesa; Antonio Ferrer-Montiel
Journal:  Eur J Neurosci       Date:  2014-02       Impact factor: 3.386

Review 8.  Neurobiology of fibromyalgia and chronic widespread pain.

Authors:  Kathleen A Sluka; Daniel J Clauw
Journal:  Neuroscience       Date:  2016-06-09       Impact factor: 3.590

Review 9.  Nociplastic pain: towards an understanding of prevalent pain conditions.

Authors:  Mary-Ann Fitzcharles; Steven P Cohen; Daniel J Clauw; Geoffrey Littlejohn; Chie Usui; Winfried Häuser
Journal:  Lancet       Date:  2021-05-29       Impact factor: 79.321

Review 10.  Fibromyalgia: Genetics and epigenetics insights may provide the basis for the development of diagnostic biomarkers.

Authors:  Simona D'Agnelli; Lars Arendt-Nielsen; Maria C Gerra; Katia Zatorri; Lorenzo Boggiani; Marco Baciarello; Elena Bignami
Journal:  Mol Pain       Date:  2018-11-29       Impact factor: 3.395

View more
  4 in total

1.  Long-lasting reflexive and nonreflexive pain responses in two mouse models of fibromyalgia-like condition.

Authors:  Beltrán Álvarez-Pérez; Meritxell Deulofeu; Judit Homs; Manuel Merlos; José Miguel Vela; Enrique Verdú; Pere Boadas-Vaello
Journal:  Sci Rep       Date:  2022-06-12       Impact factor: 4.996

Review 2.  Efficacy, Safety, and Regulation of Cannabidiol on Chronic Pain: A Systematic Review.

Authors:  Maria Resah B Villanueva; Narges Joshaghani; Nicole Villa; Omar Badla; Raman Goit; Samia E Saddik; Sarah N Dawood; Ahmad M Rabih; Ahmad Niaj; Aishwarya Raman; Manish Uprety; Maria Calero; Safeera Khan
Journal:  Cureus       Date:  2022-07-16

Review 3.  Tetrahydrocannabinol and cannabidiol medicines for chronic pain and mental health conditions.

Authors:  Jeremy D Henson; Luis Vitetta; Sean Hall
Journal:  Inflammopharmacology       Date:  2022-07-07       Impact factor: 5.093

4.  Reduced Endocannabinoid Tone in Saliva of Chronic Orofacial Pain Patients.

Authors:  Yaron Haviv; Olga Georgiev; Tal Gaver-Bracha; Sharleen Hamad; Alina Nemirovski; Rivka Hadar; Yair Sharav; Doron J Aframian; Yariv Brotman; Joseph Tam
Journal:  Molecules       Date:  2022-07-21       Impact factor: 4.927

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.